Cargando…
A terminal functionalization strategy reveals unusual binding abilities of anti-thrombin anticoagulant aptamers
Despite their unquestionable properties, oligonucleotide aptamers display some drawbacks that continue to hinder their applications. Several strategies have been undertaken to overcome these weaknesses, using thrombin binding aptamers as proof-of-concept. In particular, the functionalization of a th...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707062/ https://www.ncbi.nlm.nih.gov/pubmed/36457701 http://dx.doi.org/10.1016/j.omtn.2022.11.007 |
_version_ | 1784840639044648960 |
---|---|
author | Troisi, Romualdo Riccardi, Claudia Pérez de Carvasal, Kévan Smietana, Michael Morvan, François Del Vecchio, Pompea Montesarchio, Daniela Sica, Filomena |
author_facet | Troisi, Romualdo Riccardi, Claudia Pérez de Carvasal, Kévan Smietana, Michael Morvan, François Del Vecchio, Pompea Montesarchio, Daniela Sica, Filomena |
author_sort | Troisi, Romualdo |
collection | PubMed |
description | Despite their unquestionable properties, oligonucleotide aptamers display some drawbacks that continue to hinder their applications. Several strategies have been undertaken to overcome these weaknesses, using thrombin binding aptamers as proof-of-concept. In particular, the functionalization of a thrombin exosite I binding aptamer (TBA) with aromatic moieties, e.g., naphthalene dimides (N) and dialkoxynaphthalenes (D), attached at the 5′ and 3′ ends, respectively, proved to be highly promising. To obtain a molecular view of the effects of these modifications on aptamers, we performed a crystallographic analysis of one of these engineered oligonucleotides (TBA-NNp/DDp) in complex with thrombin. Surprisingly, three of the four examined crystallographic structures are ternary complexes in which thrombin binds a TBA-NNp/DDp molecule at exosite II as well as at exosite I, highlighting the ability of this aptamer, differently from unmodified TBA, to also recognize a localized region of exosite II. This novel ability is strictly related to the solvophobic behavior of the terminal modifications. Studies were also performed in solution to examine the properties of TBA-NNp/DDp in a crystal-free environment. The present results throw new light on the importance of appendages inducing a pseudo-cyclic charge-transfer structure in nucleic acid-based ligands to improve the interactions with proteins, thus considerably widening their potentialities. |
format | Online Article Text |
id | pubmed-9707062 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society of Gene & Cell Therapy |
record_format | MEDLINE/PubMed |
spelling | pubmed-97070622022-11-30 A terminal functionalization strategy reveals unusual binding abilities of anti-thrombin anticoagulant aptamers Troisi, Romualdo Riccardi, Claudia Pérez de Carvasal, Kévan Smietana, Michael Morvan, François Del Vecchio, Pompea Montesarchio, Daniela Sica, Filomena Mol Ther Nucleic Acids Original Article Despite their unquestionable properties, oligonucleotide aptamers display some drawbacks that continue to hinder their applications. Several strategies have been undertaken to overcome these weaknesses, using thrombin binding aptamers as proof-of-concept. In particular, the functionalization of a thrombin exosite I binding aptamer (TBA) with aromatic moieties, e.g., naphthalene dimides (N) and dialkoxynaphthalenes (D), attached at the 5′ and 3′ ends, respectively, proved to be highly promising. To obtain a molecular view of the effects of these modifications on aptamers, we performed a crystallographic analysis of one of these engineered oligonucleotides (TBA-NNp/DDp) in complex with thrombin. Surprisingly, three of the four examined crystallographic structures are ternary complexes in which thrombin binds a TBA-NNp/DDp molecule at exosite II as well as at exosite I, highlighting the ability of this aptamer, differently from unmodified TBA, to also recognize a localized region of exosite II. This novel ability is strictly related to the solvophobic behavior of the terminal modifications. Studies were also performed in solution to examine the properties of TBA-NNp/DDp in a crystal-free environment. The present results throw new light on the importance of appendages inducing a pseudo-cyclic charge-transfer structure in nucleic acid-based ligands to improve the interactions with proteins, thus considerably widening their potentialities. American Society of Gene & Cell Therapy 2022-11-15 /pmc/articles/PMC9707062/ /pubmed/36457701 http://dx.doi.org/10.1016/j.omtn.2022.11.007 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Troisi, Romualdo Riccardi, Claudia Pérez de Carvasal, Kévan Smietana, Michael Morvan, François Del Vecchio, Pompea Montesarchio, Daniela Sica, Filomena A terminal functionalization strategy reveals unusual binding abilities of anti-thrombin anticoagulant aptamers |
title | A terminal functionalization strategy reveals unusual binding abilities of anti-thrombin anticoagulant aptamers |
title_full | A terminal functionalization strategy reveals unusual binding abilities of anti-thrombin anticoagulant aptamers |
title_fullStr | A terminal functionalization strategy reveals unusual binding abilities of anti-thrombin anticoagulant aptamers |
title_full_unstemmed | A terminal functionalization strategy reveals unusual binding abilities of anti-thrombin anticoagulant aptamers |
title_short | A terminal functionalization strategy reveals unusual binding abilities of anti-thrombin anticoagulant aptamers |
title_sort | terminal functionalization strategy reveals unusual binding abilities of anti-thrombin anticoagulant aptamers |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707062/ https://www.ncbi.nlm.nih.gov/pubmed/36457701 http://dx.doi.org/10.1016/j.omtn.2022.11.007 |
work_keys_str_mv | AT troisiromualdo aterminalfunctionalizationstrategyrevealsunusualbindingabilitiesofantithrombinanticoagulantaptamers AT riccardiclaudia aterminalfunctionalizationstrategyrevealsunusualbindingabilitiesofantithrombinanticoagulantaptamers AT perezdecarvasalkevan aterminalfunctionalizationstrategyrevealsunusualbindingabilitiesofantithrombinanticoagulantaptamers AT smietanamichael aterminalfunctionalizationstrategyrevealsunusualbindingabilitiesofantithrombinanticoagulantaptamers AT morvanfrancois aterminalfunctionalizationstrategyrevealsunusualbindingabilitiesofantithrombinanticoagulantaptamers AT delvecchiopompea aterminalfunctionalizationstrategyrevealsunusualbindingabilitiesofantithrombinanticoagulantaptamers AT montesarchiodaniela aterminalfunctionalizationstrategyrevealsunusualbindingabilitiesofantithrombinanticoagulantaptamers AT sicafilomena aterminalfunctionalizationstrategyrevealsunusualbindingabilitiesofantithrombinanticoagulantaptamers AT troisiromualdo terminalfunctionalizationstrategyrevealsunusualbindingabilitiesofantithrombinanticoagulantaptamers AT riccardiclaudia terminalfunctionalizationstrategyrevealsunusualbindingabilitiesofantithrombinanticoagulantaptamers AT perezdecarvasalkevan terminalfunctionalizationstrategyrevealsunusualbindingabilitiesofantithrombinanticoagulantaptamers AT smietanamichael terminalfunctionalizationstrategyrevealsunusualbindingabilitiesofantithrombinanticoagulantaptamers AT morvanfrancois terminalfunctionalizationstrategyrevealsunusualbindingabilitiesofantithrombinanticoagulantaptamers AT delvecchiopompea terminalfunctionalizationstrategyrevealsunusualbindingabilitiesofantithrombinanticoagulantaptamers AT montesarchiodaniela terminalfunctionalizationstrategyrevealsunusualbindingabilitiesofantithrombinanticoagulantaptamers AT sicafilomena terminalfunctionalizationstrategyrevealsunusualbindingabilitiesofantithrombinanticoagulantaptamers |